Process for producing an injectable medicament preparation
OwnerFelix Kratzinventor
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.
Claims13
1-19. (canceled)
A therapeutically or diagnostically effective substance comprising at least one active compound selected from the group consisting of cytostatic agent, a cytokine, an immunosuppressive agent, a virostatic agent, an antirheumatic agent, an analgesic, an antiinflammatory agent, an antibiotic, an antimicotic agent, a signal transduction inhibitor, an angiogenesis inhibitor or a protease inhibitor, at least one protein-binding molecular residue selected from the group consisting of maleimide, haloacetamide, haloacetate, pyridylthio, N-hydroxysuccinimide ester, isothiocyanate, disulphide, vinylcarbonyl, aziridine and acetylene which is linked to the active compound through a spacer comprising an organic molecular residue, which contains at least one aliphatic carbon chain, or an aliphatic carbon ring having 1-12 carbon atoms, some of which can be replaced with oxygen, or at least one aromatic moiety, with the spacer, or the bond between the spacer and the active compound, being cleavable hydrolytically or enzymatically in the body in a pH-dependent manner, and whereas the active compound is not a cytostatic agent.
The compound of formula
A process for producing an injectable medicament preparation, which comprises a diagnostically effective substance which is dissolved in an injectable carrier liquid, wherein the diagnostically effective substance comprises a diagnostic agent selected from the group consisting of a radionuclide, a positron emitters, a NMR contrast agent, a fluorescent compound and a contrast agent in the near IR range, a spacer comprising an organic molecular residue, which contains at least one aliphatic carbon chain, or an aliphatic carbon ring having 1-12 carbon atoms, some of which can be replaced with oxygen, or at least one aromatic moiety, and at least one protein-binding molecular residue selected from the group consisting of maleimide, haloacetamide, haloacetate, pyridylthio, N-hydroxysuccinimide ester, isothiocyanate, disulphide, vinylcarbonyl, aziridine and acetylene.
The compound of the formula
Dependencies are inferred from the claim text.